

Supplemental Digital Content 5. CACNA1S Participant Description Table

Characteristics of ClinSeq® Volunteers with CACNA1S Variants						
Nucleotide Change; Predicted Protein Change	Subject No.	Race/ Ethnicity/Age/ Gender	Family History MHS, Heat Illness or Myopathy	Serum CK*^ level (U/L)	LDH (U/L)	Medical/ Surgical/ Procedures History
c.900+1G>A Splice-site	142361++	C/N/63/M	Negative	84	131	Surgeries: appendectomy 10 y
c.206C>G;p.Ala69Gly	N =70					
c.262A>G;p.Lys88Glu	102303	C/N/45/F	Negative	78	125	Negative
c.502C>T;p.Arg168*	197875	C/N/61/M	Negative	313	174	Colonoscopies x3
c.530C>T;p.Ser177Leu	102072	C/N/60/F	Negative	139^	149	Hypothyroidism on THR (TSH 6.31 mIU/mL / FT4 1.7 ng/dL)
	155322	C/N/65/F	Negative	111	150	Colonoscopies x2
	198019	C/N/60/F	Negative	52	149	Surgeries: total abdominal hysterectomy, bilateral salpingo-oophorectomy 55 y Hypothyroidism on THR
c.743C>T;p.Thr248Met	146006	C/N/58/F	Negative	84*	180	Surgeries: total abdominal hysterectomy 52 y Hypothyroidism on THR
c.773G>T;p.Gly258Val	148573	C/N/61/M	Negative	153	140	Hypothyroidism on THR
	150635	C/N/45/F	Negative	48	159	Alcohol over consumption: self-reports ≥3 glasses of wine daily
c.773G>A;p.Gly258Asp	N =14					
c.862T>G;p.Cys288Gly	100395	C/N/60/F	Negative	79	130	Negative
c.895T>C;p.Tyr299His	177243+	AA/N/58/F	Negative	247	223	Negative
	179265+	AA/N/52/F	Negative	143	161	Negative
c.1112C>T;p.Thr371Met	180133	AA/N/58/F	Negative	108	161	Colonoscopy 56 y
c.1166A>T;p.Asp389Val	195059	C/N/59/F	Negative	74	147	Surgeries: unilateral salpingo-oophorectomy
c.1301T>C;p.Phe434Ser	107143	C/N/62/M	Negative	264*	171	Negative
	122640	C/N/49/F	Negative	52	133	Duane syndrome
	115837	C/N/48/F	Negative	87*	121	Cardiac catheterizations 46 y, 48 y

Characteristics of ClinSeq® Volunteers with CACNA1S Variants						
Nucleotide Change; Predicted Protein Change	Subject No.	Race/ Ethnicity/Age/ Gender	Family History MHS, Heat Illness or Myopathy	Serum CK*^ level (U/L)	LDH (U/L)	Medical/ Surgical/ Procedures History
	182995	C/N/53/F	Negative	63*	122	Colonoscopy 52 y
	130259	C/N/59/F	Negative	99	153	Negative
c.1313T>G;p.Val438Gly	126157	C/N/53/F	Negative	90	205	Surgeries: total abdominal hysterectomy, bilateral salpingo-oophorectomy 50 y Sarcoidosis
c.1348G>A;p.Ala450Thr	186925	C/N/54/F	Negative	65	124	Surgeries: mitral valve repair 54 y
c.1373T>A;p.Leu458His	N =419					
c.1493G>A;p.Arg498His	192035	C/N/56/M	Negative	83	174	Colonoscopies x2
c.1519G>A;p.Gly507Ser	190479	C/N/51/F	Negative	114	200	Hypothyroidism on THR
c.1547C>T;p.Ser516Leu	150738	C/N/61/F	Negative	56	164	Negative
	179902	C/N/53/M	Negative	68	188	Marfan Syndrome
	154722	C/N/60/F	Negative	113*	192	Hypothyroidism on THR (TSH 0.15 mIU/mL / FT4 1.7 ng/dL)
c.1745G>C;p.Gly582Ala	100733	A/N/51/M	Negative	217*	182	Negative
c.1817G>A;p.Ser606Asn	N =16					
c.1903A>G;p.Met635Val	105733	C/N/61/M	Negative	70*	139	Surgeries: cardiac stenting 61 y
	184006	C/N/56/M	Negative	186	145	Negative
c.2047C>T;p.Arg683Cys	136532	AA/N/50/M	Negative	782*	145	Hyperuricemia 9.7 mg/dL
c.2440G>A;p.Ala814Thr	117126+	C/N/63/M	Negative	143	126	Negative
	165903	C/N/59/F	Negative	71*	177	Negative
c.2467C>T;p.Arg823Trp	107509	A/N/52/M	Negative	61*	115	Surgeries: cardiac stenting 52 y
c.2630C>T;p.Ala877Val	174649	C/N/56/M	Negative	135*	166	Surgeries: unilateral nephrectomy 40s, cardiac stenting 56 y. Colonoscopy 52 y
c.2957G>A;p.Arg986His	132619	C/N/61/F	Negative	174^	177	Sjogren's syndrome types I & II. Hypothyroidism on THR (TSH 6.53 mIU/mL /

Characteristics of ClinSeq® Volunteers with CACNA1S Variants						
Nucleotide Change; Predicted Protein Change	Subject No.	Race/ Ethnicity/Age/ Gender	Family History MHS, Heat Illness or Myopathy	Serum CK*^ level (U/L)	LDH (U/L)	Medical/ Surgical/ Procedures History
c.2992G>A;p.Asp998Asn	185599	AA/N/48/F	Negative	99	114	FT4 1.5 ng/dL
c.3026C>T;p.Thr1009Met	131005	C/N/63/F	Negative	168	171	Negative
c.3190G>A;p.Val1064Ile	151708	C/N/55/M	Negative	396	166	Circumferential Pulmonary-Vein Ablation for Chronic Atrial Fibrillation 50s, colonoscopy
c.3364T>C;p.Tyr1122His	152465	A/N/63/M	Negative	59*	138	Negative
c.3733A>C;p.Lys1245Gln	179603	C/N/58/M	Negative	68*^	135/ 4.5	Surgeries: cardiac stenting. TSH =6.39 mIU/mL/ FT4=1.1 ng/dL
c.3811G>A;p.Ala1271Thr	197544	AA/N/47/F	Negative	102	180	Negative
c.3905G>A;p.Arg1302Gln	142624	C/N/58/F	Negative	80*	168	Surgeries: knee replacement, total abdominal hysterectomy, bilateral salpingo-oophorectomy
c.4060A>T;p.Thr1354Ser	147218	C/N/48/M	Negative	375*^	205	TSH =4.3 mIU/mL, FT4=1.3 ng/dL
	112126	C/N/61/F	Negative	61	143	Negative
	139980	C/N/61/M	Negative	314*	195	Negative
	117247	C/N/55/F	Negative	59*	146	Hypothyroidism on THR
	104923	C/N/63/F	Negative	100	207	Negative
	141060	C/N/61/F	Negative	93	190	Negative
	195817	C/N/62/M	Negative	132*	132	Surgeries: cardiac stent at 62 y. Colonoscopies x3
	154231	C/N/58/M	Negative	107*	161	Negative
c.4415G>A;p.Arg1472His	159259	C/N/45/M	Negative	264	175	Negative
c.4483_4485del;p.Lys1496del	151463	A/N/57/M	Negative	136^	165	Negative
c.4615C>T;p.Arg1539Cys	N =172					
c.4718C>T;p.Thr1573Met	184042	C/N/56/F	Negative	51	158	Negative
c.4731C>G;p.Asp1577Glu	125959	C/N/59/F	Negative	168*	232	Hypothyroidism on THR (TSH 0.26 mIU/mL/ FT4 1.7 ng/dL)

Characteristics of ClinSeq® Volunteers with CACNA1S Variants						
Nucleotide Change; Predicted Protein Change	Subject No.	Race/ Ethnicity/Age/ Gender	Family History MHS, Heat Illness or Myopathy	Serum CK*^ level (U/L)	LDH (U/L)	Medical/ Surgical/ Procedures History
c.4747G>A;p.Glu1583Lys	166268	C/N/60/M	Negative	86	175	Negative
	179304	C/N/45/F	Negative	36	134	Surgeries: total abdominal hysterectomy 44 y
	120632	C/N/59/M	Negative	48	114	Negative
c.4885_4886del; Gln1629Valfs*3	114693	C/N/41/M	Negative	83	126	Surgeries: hip replacement 49 y
c.4954C>T;p.Arg1652Cys	101892	C/N/57/M	Negative	163^	142	TSH =7.74 mIU/mL, FT4=1.4 ng/dL
c.4973G>A;p.Arg1658His	N =116					
c.4984A>T;p.Asn1662Tyr	152700	C/N/51/F	Negative	123*	216	Cardiac catheterization 51 y
c.5005G>A;p.Ala1669Thr	183652	C/N/59/F	Negative	77*	156	Surgeries: CABG 51 y, cardiac stents 57.
c.5299C>T;p.Pro1767Ser	169812	C/N/52/M	Negative	252^	164	TSH =6.57 mIU/mL, FT4=1.1 ng/dL
c.5399T>C;p.Leu1800Ser	N =242					
c.5510A>C;p.Glu1837Ala	138326	C/HL/46/M	Negative	164	131	Negative
	147197	C/N/50/M	Negative	123*	134	Negative
c.5515C>T;p.Pro1839Ser	116697	C/N/64/M	Negative	112	145	Negative
	136180	C/N/59/F	Negative	270	177*	Surgeries: cardiac stent
	139001	C/N/55/F	Negative	65*	129	Negative
	114451	C/N/57/F	Negative	50	72	Hypothyroidism on THR (TSH 0.36 mIU/mL/ FT4 1.3 ng/dL)
	115065	C/N/59/M	Negative	120	179	Negative
	184131	C/N/54/M	Negative	84*	176	Procedures: Endoscopic balloon dilation -esophageal stricture. Gilbert's Disease. TSH =5.31 mIU/mL, FT4=1.1 ng/dL
	119657	C/N/52/M	Negative	118	177	Negative
	118481	C/N/62/M	Negative	182*	149	Colonoscopy
	158592	C/N/64/M	Negative	169*	166	Cardiac catheterization
c.5570G>A;p.Ser1857Asn	146462	C/N/57/M	Negative	114*	161	Negative

Participant information for *CACNA1S* variants identified in the 870 Clinseq[®] cohort. Medical histories were reviewed for surgeries/ procedures and clinical conditions indicative of myopathy or that elevate serum creatine kinase (CK). Participants were evaluated for: any myopathy, MHS, and/or exertional heat illness; history of elevated CK; hypothyroidism and/or elevated thyroid stimulating hormone (TSH) > 4.00 mIU/mL; hypokalemia <3.3 mmol/L; hyperuricemia > 8.6 mg/dL (uric acid normal range: 3.7-8.6 mg/dL); Statin and Nicotinic Acid use; self-report alcohol use (≥ 3 bottles/glasses/shots per days); autoimmune conditions: rheumatoid arthritis, psoriasis, lupus, Sjogren's syndrome, scleroderma; and renal disease. Participants race and ethnicity were determined by self report.

Age =age at enrollment. CABG =coronary artery bypass graft. CHCT =caffeine halothane contracture test.
CK =creatine kinase, range: Female =38-252 U/L; Male =52-386 U/L. Ethnicity: N =Not Hispanic or Latino; HL =Hispanic or Latino. LDH =lactate dehydrogenase, range = 113-226 U/L. K+ =potassium, range = 3.3-5.1 mmol/L. MHS =Malignant Hyperthermia Susceptible. Nucleotide change =NM_000540.2. Race: C =Caucasian, A =Asian, AA =African American, O =other, “—” = Not reported. THR =thyroid replacement hormone. TSH range: 0.40–4.00 mIU/mL. Thyroxin, FT4 range =0.9 - 1.5 ng/dL. TURP =transurethral resection of the prostate. “+” =participant has an *RYR1* variant. “++” =participant with two *RYR1* variants. “★” =participant with another *CANA1S* variant. “*” =on Statin. “^” =elevated serum TSH level. “V” =low serum TSH level. “---” =sample hemolyzed.